Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Safety and tolerability of phenserine confirmed in phase I clinical trial

March 31, 2000

SmithKline Beecham claims 5-HT6 antagonists for ADHD

March 30, 2000

ACS news: subtype-selective NMDA receptor antagonists with potential in PD

March 30, 2000

Study indicates functional abnormalities in children with ADHD

March 30, 2000

Repligen initiates largest-ever study in autism

March 30, 2000

Vanguard Medical signs collaboration with WIBR for CNS disorders

March 30, 2000

R.W. Johnson presents R&D on nicotinic acetylcholine receptor ligands

March 29, 2000

FK-960, a novel antidementia agent in phase II, increases synapse density in aged rats

March 29, 2000

The FDA approves Zonegran for the treatment of epilepsy

March 29, 2000

Discovery of ischemia-selective NMDA antagonists reported at ACS by Cambridge NeuroScience

March 29, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...